A Phase 3 clinical trial involving somatropin recombinant, marketed as Jinpei Growth Hormone Injection, was registered on September 25, 2026. The study is titled "A Phase III Clinical Study of Jinpei Growth Hormone Injection in the Treatment of Short Stature Children With Small for Gestational Age (SGA)." Its registry identifier is NCT07841678.
The trial's current status is listed as not yet recruiting. This means enrollment of participants has not begun as of the date reflected in the registry entry. The study is designated as a Phase 3 trial, a stage typically used to evaluate a treatment in a larger patient population.
No results, outcomes, or efficacy data have been posted for this trial at this time. The registry entry reflects only the trial's design, phase, and status as recorded. Somatropin recombinant remains classified under unapproved research status in this context, and this listing does not constitute regulatory approval or endorsement of any use.
Readers interested in background information can consult the compound overview for additional context on somatropin recombinant.